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Use of beta-antagonists or HMG-CoA reductase inhibitors for cardioprotection during
chemotherapy in oncology patients
Nicole Streich, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Abstract
Over the years, oncologists are better able to fight cancer and have
increased cancer survival, but we are also finding that these lifesaving
therapies can affect the heart and other parts of the body in a negative
way. Chemotherapy is excellent at destroying cancer cells, but it also
causes collateral damage to other healthy cells. There are certain
chemotherapeutic agents that are known to cause cardiotoxicity. Currently
we are monitoring the heart function of the patients who are receiving
these cardiotoxic drugs prior to starting the chemotherapy as well as
during and after treatment. However, there are currently no
recommendations for what can be done to prevent the cardiotoxicity. The
intention of this scholarly review is to look into the benefits and compelling
results in adrenergic beta-antagonists and HMG-CoA-reductase inhibitors
to reduce the risk of cardiotoxicity during chemotherapy in oncology
patients. The goal of this paper is to look at the research and hopefully
conclude that either beta-antagonists or hmg-CoA reductase are a reliable
option to prevent chemotherapy-induced cardiotoxicity. An extensive
literature review was performed and at this time, there are no concrete
benefits of using either a beta-blocker or a statin to reduce chemotherapyinduced cardiotoxicity. In the research that has been done, there is some
evidence of using these agents to protect the heart. More long-term
studies need to be conducted as well as more precise inclusion terms
need to be used, such as the exact chemotherapy regimen or the
particular cardioprotective medication that is used in the study. At this
time, recommendations to prevent chemotherapy-induced cardiotoxicity
remains inconclusive.

Introduction

Statement of the Problem
It is known that certain chemotherapeutic agents have the potential to lead
to cardiac damage, but there is no known method to protect the heart cells
from these drugs. Monitoring for damage prior to starting the chemotherapy
treatment, during the course of treatment, and following the completion of
treatment is already being done for patients that are receiving
chemotherapeutic agents known to cause cardiotoxicity. Methods to
prevent this myocardial damage are still being researched. In particular,
research is being done to look at the benefit of using beta-antagonists or
hmg-CoA reductase to prevent chemotherapy-induced cardiotoxicity.
Adrenergic beta-antagonists or HMG-CoA-reductase inhibitors may be the
answer to cardiotoxic protection for adults who are receiving cardiotoxic
chemotherapy.

Research Question
In adult oncology patients, do either adrenergic beta-antagonists or HMGCoA-reductase inhibitors reduce the risk of cardiotoxicity in patients
receiving chemotherapy?

Literature Review
Etiology, prevalence, and outcomes of cardiotoxicity in adult patients
receiving chemotherapy.
 Cardiac toxicity has been related to many cytotoxic agents including;
anthracyclines, anthraquinolones, antimetabolites, antimicrotubules,
vinca alkaloids, and tyrosine-kinase inhibitors, Babiker et al. (2018).
There is no consistency in how heart failure or cardiotoxicity is defined
and there was varying degrees of heart function prior to starting therapy.
 Cardiotoxicity related to doxorubicin therapy is unusual in adults at
cumulative doxorubicin doses less than 300 mg/m^2, and the rate of
heart failure is approximately 7-26% at 550 mg/m^2 and at a rate of
18-48% at a cumulative dose of 700 mg/m^2. Due to the potential of
heart failure, there is a maximum lifetime cumulative dose of
anthracyclines that is recommended. The recommended cumulative
lifetime dose is 400-550 mg/m^2 for adults.
 Asymptomatic systolic or diastolic heart failure are the most common
signs of chronic cardiotoxicity in cancer survivors, Chang et al. (2018).
This makes close monitoring an essential step not only just during
treatment but afterwards as well. Study limited by small sample size.
 The cumulative doxorubicin dose seems to be the best predictor of
heart failure with a median dose of 390 mg/m^2 in the patients who
developed heart failure and 180 mg/m^2 in those patients who did not
develop heart failure. In patients who received greater than 400
mg/m^2, the incidence of congestive heart failure was 3%, 7% in those
patients that received 400-550 mg/m^2, and 18% in patients who
received doses greater than 550 mg/m^2, Nathan et al. (2016)
Limitations include varying comorbid health conditions.
 Volkova et all (2011) reported that heart failure prevalence seems to
increase at a high cumulative dose of anthracycline therapy. Research
is limited due to patients having different medical histories, varying
cancer diagnoses, and diverse treatments. Table used to compare
cumulative doxorubicin dose and percentage of patients with CHF.

• Over the years, oncologists are better able to fight cancer and have
increased cancer survival, but we are also finding out that these
lifesaving therapies can affect the heart and other parts of the body in a
negative way. Since chemotherapy is not able to target just the tumor,
there is collateral damage to other cells throughout the body. This offtarget destruction can have external signs such as nausea, vomiting,
and hair loss. There is also silent internal damage being done,
sometimes to the heart and blood vessels. These injuries can appear
immediately while receiving chemotherapy or at times the damage may
not surface for years after treatment. There are not a lot of research
studies available to look at what options can be done to protect the
healthy cells from the effects of the chemotherapy. This is important to
consider because of the negative effects that are being caused by the
chemotherapy. The benefit of finding a cardioprotective agent for this
population could help save the hearts and lives of many oncology
patients.
• One of the most well known and most studied chemotherapeutic agents
that is associated with adverse cardiac events are anthracyclines, such
as doxorubicin. Anthracyclines are often used to treat adult
malignancies such as breast cancer, sarcoma, lymphoma, or
gynecological cancer. For many years, anthracycline-based
chemotherapy has caused cardiotoxicity, attributing mostly to the
creation of oxygen free radicals causing oxidative stress. More recent
research has revealed that the mechanism for anthracycline
cardiotoxicity is due to DNA damage from disruption. There are other
chemotherapeutic agents associated with cardiotoxic side effects,
Prevention of chemotherapy-induced cardiotoxicity with the use of
which include, taxanes (paclitaxel, docetaxel), alkylating agents
HMG-CoA-reductase inhibitors
(carboplatin, cisplatin), small molecule tyrosine kinase inhibitors
 Patients (n = 40) undergoing anthracycline-based chemotherapy with
(lapatinib, imatinib), and trastuzumab which is a monoclonal antibody
mean EF for the statin group was unchanged before and after
that is directed at the human epidermal growth factor receptor-2
chemotherapy (61 +/- 8% versus 63 +/- 9%, p = 0.14) but was lower in
(HER2). Clinical manifestations of cardiotoxicity include many
the control group (63 +/- 7% versus 55 +/- 10%, p < 0.0001), Sharalaya
disorders, ranging from mild transient arrhythmias and heart failure to
et al. (2018). Limited by small sample size and no long-term follow-up.
possibly deadly conditions such as myocardial infarction or ischemia
 Anthracycline-based chemotherapy in female breast cancer patients
and cardiomyopathy.
(n = 628). This study showed that patients who received HMG-CoA
• The intention of this scholarly review is to look into the benefits and
reductase, 4 patients (6%) compared to the 27 patients (13%) in
compelling results of adrenergic beta-antagonists in reducing the risk of
control group had a lower incidence of heart failure, Sharalaya et al.
cardiotoxicity during chemotherapy in cancer patients. The goal is to
(2018).
look at the research and hopefully conclude that beta-antagonists are a  Upshaw (2018) compared several medications to reduce chemotherapy
reliable option for heart protection during antineoplastic treatment.
induced cardiotoxicity. Most showed promise, including betaantagonists and HMG-CoA reductase inhibitors. This study was limited
by using various medications in one specific class.
 Riad et al. (2009) looked if fluvastatin pretreatment can attenuate
doxorubicin-induced cardiotoxicity. The study was done in mice, not
humans.

 Results of the study showed that five days following the doxorubicin
administration, untreated mice displayed significantly impaired systolic
(LVP, −29%; dP/dtmax, −45%; P < 0.05), diastolic (dP/dtmin, −44%;
stiffness, +275%; P < 0.05), and global left ventricle function (SV,
−61%; HR, −18%; CO, −68%; P < 0.05) versus the placebo group.
Therefore, Raid’s group concluded that using a statin, such as
fluvastatin, to pretreat patients receiving doxorubicin therapy helps to
prevent cardiotoxicity.
Mechanism of action of adrenergic beta-antagonists
 Beta-antagonists influence the heart by decreasing spontaneous
depolarization of pacemakers which causes prolongation of sinus node
cycle length, atrioventricular refractory period, and atrioventricular
conduction times, Gorre et al. (2010).
Prevention of chemotherapy-induced cardiotoxicity with the use of
beta-antagonists
 Carvedilol to prevent anthracycline chemotherapy cardiotoxicity using 192
Her2-negative breast cancer patients with normal LVEF, Avila et al.
(2018). Study only looked at breast cancer patients in one cancer center.
 Carvedilol did not affect early onset of LVEF reduction, but the
carvedilol did have a significant reduction in troponin levels and
diastolic dysfunction.
 Carvedilol 6.25 mg daily throughout chemotherapy in female breast
cancer patients that were planning to receive doxorubicin chemotherapy,
Beheshti et al. (2016). Study did not include any long term follow-up.
 There was a significant decrease in the control group (all p values
<0.001). The mean differences of strain parameters in the case group
were significantly less than the control group and also the strain-rate
parameters.
 Doxorubicin-induced cardiotoxicity can be reduced with carvedilol
prophylaxis.
 Efficacy of beta-antagonists and angiotensin antagonists to prevent left
ventricular dysfunction and cardiac events in cancer patients receiving
anthracycline chemotherapy, Yun et al. (2015). No long-term follow-up.
Exact medications used were not reported.
 Association of angiotensin antagonists and beta-blocker therapy with
high post-chemotherapy LVEF of 64.03% compared with 57.48% for
control treatment.
 Experimental agents such as beta-antagonists and ACE-I, were seen
to be more beneficial on LVEF preservation when the accumulative
dose of anthracycline therapy was higher.

Discussion
Chemotherapy agents can cause cardiotoxicity that can be seen as
arrhythmias, heart failure, or cardiomyopathy. These effects can be seen
throughout the course of chemotherapy or they can be seen months or even
years following the completion of chemotherapy.
HMG-CoA-reductase inhibitors
 Protect the heart through anti-inflammatory and antioxidative mechanisms
and have the potential to protect the heart from chemotherapy-induced
cardiotoxicity.
 Evidence may show that these may be beneficial to prevent chemotherapyinduced cardiotoxicity, Sharalaya et al. (2018) and the article by Upshaw
(2018).
Adrenergic beta-antagonists
 Effect the heart by reducing spontaneous depolarization of pacemakers to
cause continuation of sinus node cycle length, atrioventricular refractory
period, and atrioventricular conduction times, Gorre et al. (2010).
 Carvedilol may reduce diastolic heart failure and lower troponin I values
leading to a decreased incidence of myocardial injury, Avila et al. (2018).
 beta-antagonists and ACE inhibitors may help preserve left ventricle ejection
fraction in patients who are receiving the cardiotoxic anthracycline
chemotherapy, Yun et al. (2015). This could be related to cardioprotective
factors or it could be anthracycline dose dependent.
The use of any pharmacological therapy to reduce chemotherapy-induced
cardiotoxicity cannot yet be recommended. There is evidence that points to
both HMG-CoA-reductase inhibitors and adrenergic beta-antagonists to be
beneficial for cardioprotection. Until there is further research completed that
looks at specific chemotherapeutic agents, specific hmg-CoA reductase or
beta-antagonists, and long-term studies looking at heart function, no specific
recommendations may be made to prevent chemotherapy-induced
cardiotoxicity.

Applicability to Clinical
Practice

 Anthracycline chemotherapy along with some other antineoplastic drugs
such as taxanes, alkylating agents, small molecule tyrosine kinase
inhibitors, and trastuzumab may lead to cardiotoxicity presenting as
arrhythmias, heart failure, ischemic injury, or cardiomyopathy.
 Cardiac function is monitored before, during, and after treatment.
Unfortunately, there are no recommendations for prevention of
chemotherapy-induced cardiotoxicity at this time.
 Whether a patient is just starting their chemotherapy regimen or is five
years post-treatment, all healthcare providers should make sure to do a
thorough cardiac exam to rule out any residual damage from the
chemotherapy.
 Until further research is done regarding the use of beta-antagonists or
HMG-CoA reductase inhibitors for prevention of chemotherapy-induced
cardiotoxicity, monitoring the patient’s cardiac function is very important.
Healthcare providers need to be aware of the cardiotoxic effects that may
result during or following antineoplastic therapy. It is important for
providers to be aware of the side effects of these chemotherapeutic
agents and assess these patients with these side effects in mind.
Whether a patient is just starting their chemotherapy regimen or is five
years post-treatment, providers should make sure to do a thorough
cardiac exam to rule out any residual damage from the chemotherapy.
Dose related risk of doxorubicin-induced congestive heart failure
Volkova et al. (2011)
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